EssilorLuxottica (OTCMKTS:ESLOY) Sets New 52-Week Low – Here’s Why

Shares of EssilorLuxottica Unsponsored ADR (OTCMKTS:ESLOY) reached a new 52-week low on Tuesday . The company traded as low as $116.28 and last traded at $116.7050, with a volume of 32733 shares trading hands. The stock had previously closed at $117.72.

Analyst Ratings Changes

ESLOY has been the subject of a number of research reports. HSBC upgraded EssilorLuxottica from a “hold” rating to a “buy” rating in a research note on Wednesday, January 14th. Kepler Capital Markets upgraded shares of EssilorLuxottica from a “hold” rating to a “buy” rating in a research report on Thursday, January 15th. Citigroup reissued a “buy” rating on shares of EssilorLuxottica in a research note on Thursday, December 11th. UBS Group upgraded shares of EssilorLuxottica from a “hold” rating to a “strong-buy” rating in a research report on Thursday, November 27th. Finally, Zacks Research downgraded EssilorLuxottica from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 18th. Two analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, EssilorLuxottica has an average rating of “Buy”.

EssilorLuxottica Trading Down 0.4%

The business’s 50 day simple moving average is $145.90 and its 200-day simple moving average is $160.43. The company has a quick ratio of 0.70, a current ratio of 0.99 and a debt-to-equity ratio of 0.17.

About EssilorLuxottica

EssilorLuxottica SE is a global ophthalmic optics company formed through the 2018 merger of France-based Essilor and Italy-based Luxottica. Headquartered near Paris, the company combines lens manufacturing, frame design and production, brand management and retail operations to provide a vertically integrated offering across the vision care value chain. Its activities span product research and development, manufacturing, wholesale distribution and retailing of spectacles, sunglasses and ophthalmic lenses.

The company’s product portfolio includes prescription and non-prescription lenses, lens coatings and treatments, and an array of eyewear brands and frames.